FDA 483 - Sentio Biosciences LLC - February 06, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sentio Biosciences LLC in Maryland Heights, MO, revealed critical deficiencies in monitoring and controlling objectionable organisms within their (b)(4) system used for non-sterile API manufacturing. The firm's microbial test methods were not validated to detect Burkholderia cepacia complex, and a significant leak in the system went unaddressed for an extended period. These issues pose a high risk of microbial and chemical contamination to drug substances like Melarsomine Dihydrochloride and Pentosan Polysulfate Sodium.
ID · c7c1a696-85a1-4f44-bab0-cef58ce91d71